COMPANY
Tulavi Therapeutics
Timeline
- Trial start —: Continuous Observational Monitoring Program for Allay™ Hydrogel Cap Safety and Success Study source ↗
- FDA FDA 510(k) clearance: allay Nerve Cap (TL5515-1); allay Nerve Cap (TL5515-2); Delivery Tips (TL-7627) — K252051, Sep 29, 2025. Applicant at approval: Tulavi Therapeutics, Inc. source ↗
Upcoming milestones
- Jan 1, 2029 (ESTIMATED) · · Continuous Observational Monitoring Program for Allay™ Hydrogel Cap Safety and Success Study · NCT07246980
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07246980 | Continuous Observational Monitoring Program for Allay™ Hydrogel Cap Safety and Success Study | Not listed | Recruiting | May 6, 2026 | Jan 1, 2029 (estimated) |
FDA records (last 2 years)
- FDA 510(k) clearance: allay Nerve Cap (TL5515-1); allay Nerve Cap (TL5515-2); Delivery Tips (TL-7627) — K252051, Sep 29, 2025. Applicant at approval: Tulavi Therapeutics, Inc. source ↗
Connect
See your connections at Tulavi Therapeutics on LinkedIn (search by name, results not checked)